13 Best Hot Stocks to Buy According to Analysts

11. Capricor Therapeutics Inc. (NASDAQ:CAPR)

Capricor Therapeutics Inc. (NASDAQ:CAPR) is one of the best hot stocks to buy according to analysts. On March 12, Capricor Therapeutics presented new late-breaking data from its Phase 3 HOPE-3 clinical trial at the 2026 MDA Conference, highlighting the benefits of Deramiocel for Duchenne muscular dystrophy. Cardiac MRI results showed a reduction in myocardial fibrosis compared to the placebo group, with a notable improvement in left ventricular ejection fraction among patients with baseline cardiomyopathy. Additionally, a composite Global Statistical Test confirmed a statistically significant overall treatment benefit, integrating measures of physical function and patient perspective.

Functional outcomes also demonstrated that Deramiocel significantly slows disease progression related to daily activities. Data from the Duchenne Video Assessment specifically showed an 83% slowing of progression in tasks such as independent eating, which correlates with improved elbow and arm function observed in clinical testing. These findings suggest the therapy may help preserve patient independence by maintaining critical hand-to-mouth movements over time.

Capricor Therapeutics Inc. (NASDAQ:CAPR) is currently moving toward potential commercialization, with a BLA under FDA review. Deramiocel has already received several special designations, including Orphan Drug and Regenerative Medicine Advanced Therapy status. The FDA has set a PDUFA target action date of August 22 to decide on the therapy’s approval for the US market.

Capricor Therapeutics Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company that develops transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy/DMD and other diseases with unmet medical needs in the US.